|
|
|
|
|
by graemep
21 days ago
|
|
> Demands for increasingly byzantine trials have ballooned the costs associated with drug development, Even if that is true, is it an intrinsic problem with trials or just bad regulation? If it is the latter then you need to change the regulations? Is the problem global - is every regulator everywhere demanding byzantine trails? |
|